HTD:FRA
Corcept Therapeutics Inc
€107.70
arrow_downward
-0.60%(-0.65) 1D
Oct 13, 8:00:55 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HTD...
Open
€107.70
High
€107.70
Low
€107.70
Mkt. cap
13.10B
Avg. vol.
7.00
Volume
0.00
52-wk high
€108.65
52-wk low
€27.49
No. of employees
730
Open
€107.70
High
€107.70
Low
€107.70
Mkt. cap
13.10B
Avg. vol.
7.00
Volume
0.00
52-wk high
€108.65
52-wk low
€27.49
No. of employees
730
News stories
From web sources and news partners
Morningstar
·
49 minutes ago
XCF Global (Nasdaq:SAFX) Announces $12M+ in Gross Product Sales and Shipments of 1.4 Million Gallons of Renewable Diesel in September
FinancialContent
·
19 minutes ago
Albertsons (NYSE:ACI) Reports Q3 CY2026 In Line With Expectations
MarketBeat
·
10 minutes ago
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com